Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis

source extracted confidence: high 2026-04-09
#humans #dermatitis-atopic #janus-kinase-inhibitors #severity-of-illness-index #treatment-outcome

Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis

Kim et al., 2025 | Clin Exp Allergy | Meta Analysis

Citation

Kim Yunha, Seo Gayeong, ... Yee Jeong. Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Clin Exp Allergy. 2025-Sep;55(9):755-772. doi:10.1111/cea.70125

Abstract

OBJECTIVE: The aim of this study is to evaluate the effectiveness and safety of JAK inhibitors in patients with moderate to severe atopic dermatitis by performing a systematic review and meta-analysis using data from studies in real-world settings. DESIGN: Systematic review and meta-analysis. Pooled estimates for effectiveness and safety were assessed using the Freeman-Tukey Double ArcSine method. Statistical heterogeneity was assessed using I2 statistics. A random-effects model (DerSimonian-Laird method) was applied to consider the heterogeneity within and between studies and to give a more conservative estimate. The study quality assessment tools developed by the National Heart, Lung, and Blood Institute were used. DATA SOURCE: Relevant studies were searched in March 2025 using four databases: PubMed, Embase, Scopus, and Web of Science. ELIGIBILITY CRITERIA: Studies evaluating the effectiveness or safety of systemic JAK inhibitors among patients with moderate to severe atopic dermatitis in a real-world setting were included. RESULTS: A total of 50 studies were included in this review. Regarding their effectiveness, the pooled estimates with a 95% CI of Eczema Area and Severity Index (EASI)-75 were 44% (34%-55%), 45% (28%-62%), 59% (51%-66%), 73% (64%-81%), 70% (57%-81%), and 86% (72%-96%) at 4, 8, 12, 16, 24, and 52 weeks. For safety, the most common adverse events were acne (16%), followed by increased creatine phosphokinase levels (13%) and increased lipids (12%). CONCLUSION: Our meta-analysis of JAK inhibitors in patients with atopic dermatitis demonstrated that the overall outcomes from real-world settings are comparable to those from clinical trials. SYSTEMATIC REVIEW REGISTRATION: Protocol Registration: PROSPERO CRD42024569258.

Key Findings

A total of 50 studies were included in this review. Regarding their effectiveness, the pooled estimates with a 95% CI of Eczema Area and Severity Index (EASI)-75 were 44% (34%-55%), 45% (28%-62%), 59% (51%-66%), 73% (64%-81%), 70% (57%-81%), and 86% (72%-96%) at 4, 8, 12, 16, 24, and 52 weeks. For safety, the most common adverse events were acne (16%), followed by increased creatine phosphokinase levels (13%) and increased lipids (12%).

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population moderate to severe atopic
Sample Size 50
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Dermatitis, Atopic
  • Janus Kinase Inhibitors
  • Severity of Illness Index
  • Treatment Outcome

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Systematic Review
  • Vertical: creatine

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09